Novartis Ag (NVS) Change in Working Capital (2009 - 2026)
Novartis Ag (NVS) posted Change in Working Capital of $232.0 million for Q2 2026, up 129.48% sequentially from -$787.0 million in Q1 2026, and down 47.51% YoY from $442.0 million in Q2 2025.
Novartis Ag (NVS) Change in Working Capital (2009 - 2026) Analysis & Trends
Novartis Ag has reported Change in Working Capital for 18 years, with the latest figure at $232.0 million in Q2 2026.
- Quarterly Change in Working Capital fell 47.51% year-over-year to $232.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$1.5 billion (up 13.62% YoY) and the FY2025 annual result came in at -$26.0 million, up 96.32% from the prior year.
- Change in Working Capital rose to $232.0 million in Q2 2026 per NVS's latest filing, from -$787.0 million in the prior quarter.
- Over five years, Change in Working Capital peaked at $456.0 million in Q4 2022 and troughed at -$1.8 billion in Q4 2024.
- A 5-year average of -$220.2 million and a median of -$226.5 million in 2024 frame the typical range for Change in Working Capital.
- The widest YoY moves for Change in Working Capital: up 332.73% in 2024, down 355.99% in 2024.
- Over 5 years, Change in Working Capital stood at $456.0 million in 2022, then sank by 184.21% to -$384.0 million in 2023, then tumbled by 355.99% to -$1.8 billion in 2024, then surged by 60.31% to -$695.0 million in 2025, then jumped by 133.38% to $232.0 million in 2026.
- According to Business Quant data, Change in Working Capital over the past three periods registered $232.0 million, -$787.0 million, and -$695.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Working Capital (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 232.00 Mn |
| Jun 30, 2026 | 232.00 Mn |
| Mar 31, 2026 | -787.00 Mn |
| Mar 31, 2026 | -787.00 Mn |
| Dec 31, 2025 | -695.00 Mn |
| Dec 31, 2025 | -695.00 Mn |
| Sep 30, 2025 | -272.00 Mn |
| Sep 30, 2025 | -272.00 Mn |
| Jun 30, 2025 | 442.00 Mn |
| Jun 30, 2025 | 442.00 Mn |
| Mar 31, 2025 | -237.00 Mn |
| Mar 31, 2025 | -237.00 Mn |
| Dec 31, 2024 | -1.75 Bn |
| Dec 31, 2024 | -1.75 Bn |
| Sep 30, 2024 | -216.00 Mn |
| Sep 30, 2024 | -216.00 Mn |
| Jun 30, 2024 | 238.00 Mn |
| Jun 30, 2024 | 238.00 Mn |
| Mar 31, 2024 | -343.00 Mn |
| Mar 31, 2024 | -343.00 Mn |